Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07219121 · ClinicalTrials.gov registry record · Phase 4
Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis
A Phase 4 study of Kidney Transplant and Focal Segmental Glomerulosclerosis, sponsored by Travere Therapeutics.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
- 9
- Study locations
NCT07219121 is a Phase 4 study of Kidney Transplant and Focal Segmental Glomerulosclerosis that is actively recruiting participants, run by Travere Therapeutics. The registered enrollment target is 20 participants, below the 1,898-participant average among 30 other Kidney Transplant trials with a reported enrollment target (99% lower). The trial reports 9 study locations across 8 states.
The verdict
NCT07219121, a Phase 4 study of Kidney Transplant and Focal Segmental Glomerulosclerosis, is actively recruiting participants, sponsored by Travere Therapeutics.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
- 9
- Study locations
Study Summary
To evaluate the safety and efficacy of sparsentan tablets for the treatment of patients with proteinuria after kidney transplantation with once-daily dosing for 36 weeks.
Conditions Studied
Interventions
- DRUG Sparsentan
Study Locations (9)
Texas
- Dallas Nephrology Associates - Dallas
- University of Texas - Galveston
Alabama
- University of Alabama at Birmingham - Birmingham
New York
- Cornell Medical Center - New York
North Carolina
- University of North Carolina Chapel Hill - Morrisville
Ohio
- Ohio State University - Columbus
Pennsylvania
- University of Pittsburgh Medical Center - Pittsburgh
Washington
- University of Washington - Seattle
Wisconsin
- University of Wisconsin - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-10-07 |
| Est. Completion | 2027-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07219121
The ClinicalTrials.gov registry entry for NCT07219121 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,898-participant average among 30 other Kidney Transplant trials with a reported enrollment target (99% lower). The listed sponsor is Travere Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Kidney Transplant appearing as the primary indexed condition, and to 1 intervention - of which Sparsentan is the first listed.
NCT07219121 reports 9 study locations spanning 8 distinct geographic areas - top geographies include Texas, Alabama, New York.
Frequently Asked Questions
What is clinical trial NCT07219121 about?
NCT07219121 is a clinical study titled "Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis". To evaluate the safety and efficacy of sparsentan tablets for the treatment of patients with proteinuria after kidney transplantation with once-daily dosing for 36 weeks.
What is the current status of trial NCT07219121?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2025-10-07. Estimated completion is 2027-05.
What conditions does trial NCT07219121 study?
This clinical trial studies the following conditions: Kidney Transplant, Focal Segmental Glomerulosclerosis, Proteinuria, Immunoglobulin A (IgA) Nephropathy.
What interventions are being tested in trial NCT07219121?
The interventions under investigation include: Sparsentan (DRUG).
Who is sponsoring clinical trial NCT07219121?
This trial is sponsored by Travere Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07219121 being conducted?
This trial has 9 study locations across Alabama, New York, North Carolina, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Transplant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Empagliflozin Treatment in Kidney Transplant Recipients
RECRUITING · Phase 4
-
Immunogenicity of HPV Vaccine in Transplant Recipients.
ACTIVE NOT RECRUITING · Phase 4
-
Pharmacokinetic Study of Tacrolimus and Mycophenolate Mofetil in Kidney Transplant Recipients With Hyperkalemia Receiving Patiromer
COMPLETED · Phase 4
-
Dosing Strategies for de Novo Once-daily Extended Release Tacrolimus (LCPT) in Kidney Transplant Recipients
COMPLETED · Phase 4
-
Safety and Tolerability of Vertebral Bone Marrow-derived Mesenchymal Stem Cells (BM-MSC) in Real World Scenarios of Patients With Chronic Kidney Disease (CKD)
RECRUITING
-
Social Support Counseling Intervention for Kidney Transplant Candidates
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.